GLP-1 RAs to assist with weight loss have exploded in popularity. Researchers are working to identify which patients will ...

The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes ...

Based on the review, the researchers promote the integration of GLP-1 receptor agonists as a primary treatment for obesity in ...

A new study provides more evidence that GLP-1 RAs don’t raise the risk for pancreatic cancer and may in fact offer some protection.

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Glatter is an assistant professor of emergency medicine.

GLP-1 drugs like Ozempic are injectable medications—but a strange new market has emerged selling oral “compounded” versions ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out drugs are emerging.

Glucagon-like peptide-1 receptor agonists are FDA-approved medications that mimic the action of a naturally occurring hormone ...

On November 18, at the American Heart Association (AHA) 100th Annual Meeting 2024, the safety of glucagon-like peptide-1 ...

So, you have managed to shed 30 pounds with the help of one of the new blockbuster GLP-1 drugs, but as the holidays ...

Coya Therapeutics (COYA) releases the following letter to stockholders from Chief Executive Officer Dr. Arun Swaminathan….”Given my recent ...

Lilly will provide the funding and expertise to advance Laekna’s LAE102, a first-in-class monoclonal antibody targeting the ...